{"id":"W4379981428","doi":"10.1002/hon.3163_t05","title":"SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Astellas Pharma; Pfizer","keywords":"Medicine; Rituximab; Brentuximab vedotin; Internal medicine; Oncology; Refractory (planetary science); Lymphoma; Chimeric antigen receptor; Phases of clinical research; Clinical trial; Immunotherapy; Cancer; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007879268,0.0008074136,0.001061628,0.0002382835,0.000244935,0.001030465,0.0006852503,0.0008187387,0.005052322],"category_scores_gemma":[0.0004375287,0.0003935101,0.001133387,0.0002183671,0.0004927135,0.0005431098,0.0003023023,0.002145457,0.0008817834],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009748928,"about_ca_system_score_gemma":0.0008175117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001093962,"about_ca_topic_score_gemma":0.004248444,"domain_scores_codex":[0.9998279,0.00007517958,0.000008873043,0.00003109853,0.00001965532,0.00003734213],"domain_scores_gemma":[0.999773,0.00003401679,0.0000472411,0.00001553335,0.0000117874,0.0001184958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6973245,0.01641221,0.004407679,0.002967837,0.002864332,0.0002137305,0.0003806165,0.002667412,0.02827828,0.0008629233,0.01023133,0.2333893],"study_design_scores_gemma":[0.7705871,0.197984,0.0159553,0.0002438028,0.0008894597,0.0004278853,0.0001038583,0.001818473,0.002431159,0.0005369661,0.008977949,0.00004399768],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831308,0.008000476,0.0003294754,0.001026428,0.0003761748,0.001408354,0.001615086,0.0001861897,0.003926974],"genre_scores_gemma":[0.9834426,0.004976696,0.001047869,0.00138815,0.0001951607,0.001470055,0.002083736,0.00002535096,0.005370377],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005052322,"threshold_uncertainty_score":0.01690173,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0644506952634808,"score_gpt":0.3914333370511365,"score_spread":0.3269826417876557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}